


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-3 CANCELED

4. (currently amended) A compound comprising the structure of formula I:  
wherein:




- Ring A is optionally substituted with one to five substituents selected from
  - a) a  $C_1$ ,  $C_2$ ,  $C_3$ ,  $C_4$  or  $C_5$  branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy; or
  - b) a halogen or trihaloalkyl;
- Ring B comprises at least one structure denoted by  $R_a$  and  $R_b$  which represent an *ortho*-quinone moiety  $-(C=O)-(C=O)-$ , *ortho*-catechol  $-(C-OH)-(C-OH)-$  or *ortho*-catechol pro-drug moiety  $-(C-O-Prodrug\ moiety)-(C-O-Prodrug\ moiety)-$ ; and the remaining carbons of Ring B are optionally substituted with one to five substituents selected from
  - a) a  $C_1$ ,  $C_2$ ,  $C_3$ ,  $C_4$  or  $C_5$  branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;
  - b) a halogen or trihaloalkyl;
  - c) a  $C_1$ ,  $C_2$ ,  $C_3$ ,  $C_4$  or  $C_5$  branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy; or
  - d) an OH, or a  $C_1$ ,  $C_2$ ,  $C_3$ ,  $C_4$  or  $C_5$  primary, secondary, or tertiary alcohol;
  - e) nitro; and
- Bridge X is an alkene  $-(CR_9=CR_{10})-$ , wherein  $R_9$  and  $R_{10}$  are alternatively H, alkyl, amino, amido, cyano, hydroxyl, or carboxyl;


provided that said compound is not combretastatin A1 or a salt, ester, or prodrug thereof.

Claims 5 - 9 CANCELED

10. (currently amended) A compound comprising a quinone, quinone prodrug, or a pharmaceutically acceptable salt form thereof having one of the following general structures:



or



wherein:

a. R<sub>1</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>7</sub> are H;

—R<sub>4</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are the same or different and are selected from hydrogen and:

- i) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;
- ii) a halogen or trihaloalkyl;
- iii) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy; or
- iv) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> primary, secondary, or tertiary alcohol;

R<sub>8</sub> is selected from:

- i) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;

ii) a halogen or trihaloalkyl;

iii) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy;

iv) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> primary, secondary, or tertiary alcohol; or

v) nitro;

~~and the remaining R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, or R<sub>8</sub> are H; and~~

b. X is an alkene (-CR<sub>9</sub>=CR<sub>10</sub>-), wherein R<sub>9</sub> and R<sub>10</sub> are alternatively H, alkyl, amino, amido, cyano, hydroxyl, or carboxyl

provided that said compound is not combretastatin A1 or a salt, ester, or prodrug thereof.

11. (canceled)

12. (previously presented) The compound of claim 10, wherein X is an ethylene group (-CH=CH-), and Rings A and B are in a cis (Z) isomeric configuration.

13. (original) The compound of claim 12, wherein R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are methoxy.


14. (canceled)

15. (currently amended) The compound of claim ~~44~~ 10, wherein R<sub>8</sub> is ~~OH or~~ -O-CH<sub>2</sub>-CH=CH<sub>2</sub>.

16. (original) The compound of claim 4, wherein said catechol is a biooxidative agent which is oxidatively activated *in vivo* to form a quinone capable of participating in a redox cycling reaction to form one or more Reactive Oxygen Species ("ROS").

Claims 17-33 CANCELED

34. (currently amended) A composition of the following formula (V):



wherein

- a. Z is an ethylene (-CH=CH-) bridge in the cis (Z) isomeric configuration;
- b. R<sub>1</sub> and R<sub>2</sub> are OH or a prodrug form thereof;
- c. R<sub>3</sub> is
  - i) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;
  - ii) a halogen or trihaloalkyl;
  - iii) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy;
  - iv) an OH, or a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> primary, secondary, or tertiary alcohol; or
  - v) oxo, lower alkanoyl, thio, sulfonyl, sulfonamide, nitro, nitrosyl, cyano, carboxy, carbamyl, aryl, or heterocycle;
- d. R<sub>4</sub>, R<sub>5</sub>, and R<sub>9</sub> are hydrogen,
- e. R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>8</sub> are the same or different and selected from hydrogen and
  - i) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> branched or straight-chain lower alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, or lower alkanoyloxy;
  - ii) a halogen or trihaloalkyl;
  - iii) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> branched or straight chain lower alkyl, allyl, allyloxy, vinyl, or vinyloxy; or
  - iv) a C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub> or C<sub>5</sub> primary, secondary, or tertiary alcohol;
  - v) nitro; and

~~the remaining R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are hydrogen,~~

provided that said compound is not combretastatin A1 or prodrug thereof.

35. (currently amended) The composition of claim 34, wherein ~~at least three of~~ R<sub>6</sub>, R<sub>7</sub>, and ~~R<sub>8</sub>, and R<sub>9</sub>~~ are not hydrogen.

36. (original) The composition of claim 35, wherein R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are the same.

37. (original) The composition of claim 36, wherein R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are methoxy.

38. (canceled)

39. (currently amended) The composition of claim ~~38~~ 37, wherein R<sub>3</sub> is -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>2</sub>CH<sub>3</sub>, -F, -Br, -CF<sub>3</sub>, -CBr<sub>3</sub>, ~~-OH~~, -O-CH<sub>2</sub>-CH=CH<sub>2</sub>, -CH<sub>2</sub>-CH=CH<sub>2</sub>, -NO<sub>2</sub>, -cyano, or -carboxy.

40. (currently amended) The composition of claim ~~39~~ 36, wherein R<sub>6</sub>, R<sub>7</sub>, and R<sub>8</sub> are F.

41. (canceled)

42. (currently amended) The composition of claim ~~44~~ 40, wherein R<sub>3</sub> is -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>2</sub>CH<sub>3</sub>, -F, -Br, -CF<sub>3</sub>, -CBr<sub>3</sub>, ~~-OH~~, -O-CH<sub>2</sub>-CH=CH<sub>2</sub>, -CH<sub>2</sub>-CH=CH<sub>2</sub>, -NO<sub>2</sub>, -cyano, -carboxy, or -benzyl.

Claims 43-56 CANCELED

57. (currently amended) A composition selected from the group consisting of

~~6-[(Z)-2-(3,4,5-Trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,~~  
3-Ethyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,  
3-Methyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,  
4-Bromo-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,  
4-Phenyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,  
3-Allyl-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,  
4-Fluoro-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-dihydroxybenzene,  
2,3,4-Trihydroxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-benzene,  
2,3-Dihydroxy-4-ethoxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-benzene,  
2,3-Dihydroxy-4-allyloxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-benzene,  
4-Nitro-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-2,3-dihydroxybenzene,

2',3'dihydroxy -3,5 dichloro4,4'-dimethoxy-(Z)-stilbene,  
2',3' dihydroxy-4'-methoxy-3,4,5-trifluoro-(Z)-stilbene,  
2,3-Dihydroxy-4-methoxy-[(Z)-2-(3,4,5-trimethoxyphenyl) Beta-lactam]-benzene,  
2',3' diphosphate-3,4,5-trimethoxy-(Z)-stilbene, tetrasodium salt;  
3',4' diphosphate-3,4,5-trimethoxy-(Z)-stilbene, tetrasodium salt;  
and combinations thereof.

58.(previously presented) The compound of claim 4, wherein X is an ethylene group (-CH=CH-), and Rings A and B are in a cis (Z) isomeric configuration